Abstract
A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer. The drug was instilled weekly for 8 weeks. Thirty-nine patients (56 per cent) had failed thiotepa therapy and 25 had high grade tumors. Of the patients 27 (39 per cent) had complete eradication of tumor at the initial 3-month evaluation and an additional 27 had a partial response. The response did not vary with initial tumor grade or stage. Followup averaged 28 months for the 70 patients. A muscle invasive tumor developed during followup in 7 per cent of the patients with an initial complete response, 15 per cent with a partial response and 25 per cent of the initial failures. To date 5 patients (7 per cent) have died of bladder cancer. Intravesical mitomycin C is an effective modality for treatment of superficial bladder cancer. Patients achieving a complete response are at little risk for progressive disease.
| Original language | English |
|---|---|
| Pages (from-to) | 1107-1109 |
| Number of pages | 3 |
| Journal | Journal of Urology |
| Volume | 134 |
| Issue number | 6 |
| State | Published - Dec 1 1985 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Treatment of superficial bladder cancer with intravesical mitomycin C : Analysis of immediate and long-term response in 70 patients. / Soloway, M. S.
In: Journal of Urology, Vol. 134, No. 6, 01.12.1985, p. 1107-1109.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of superficial bladder cancer with intravesical mitomycin C
T2 - Analysis of immediate and long-term response in 70 patients
AU - Soloway, M. S.
PY - 1985/12/1
Y1 - 1985/12/1
N2 - A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer. The drug was instilled weekly for 8 weeks. Thirty-nine patients (56 per cent) had failed thiotepa therapy and 25 had high grade tumors. Of the patients 27 (39 per cent) had complete eradication of tumor at the initial 3-month evaluation and an additional 27 had a partial response. The response did not vary with initial tumor grade or stage. Followup averaged 28 months for the 70 patients. A muscle invasive tumor developed during followup in 7 per cent of the patients with an initial complete response, 15 per cent with a partial response and 25 per cent of the initial failures. To date 5 patients (7 per cent) have died of bladder cancer. Intravesical mitomycin C is an effective modality for treatment of superficial bladder cancer. Patients achieving a complete response are at little risk for progressive disease.
AB - A total of 70 patients received intravesical mitomycin C for treatment of superficial bladder cancer. The drug was instilled weekly for 8 weeks. Thirty-nine patients (56 per cent) had failed thiotepa therapy and 25 had high grade tumors. Of the patients 27 (39 per cent) had complete eradication of tumor at the initial 3-month evaluation and an additional 27 had a partial response. The response did not vary with initial tumor grade or stage. Followup averaged 28 months for the 70 patients. A muscle invasive tumor developed during followup in 7 per cent of the patients with an initial complete response, 15 per cent with a partial response and 25 per cent of the initial failures. To date 5 patients (7 per cent) have died of bladder cancer. Intravesical mitomycin C is an effective modality for treatment of superficial bladder cancer. Patients achieving a complete response are at little risk for progressive disease.
UR - http://www.scopus.com/inward/record.url?scp=0022384393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022384393&partnerID=8YFLogxK
M3 - Article
VL - 134
SP - 1107
EP - 1109
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 6
ER -